Table 3.
T. cruzi immunophenotyping in patients from Latin America
| Sample origin | TSSA reactivity | Total | ||
|---|---|---|---|---|
| I | II | I–II | ||
| Mexico | 10 (33%) | 11 (37%) | 9 (30%) | 30 |
| Colombia | 16 (17%) | 41 (44%) | 36 (39%) | 93 |
| Venezuela | 14 (34%) | 19 (46%) | 8 (19%) | 41 |
| Argentina | 0 (0%) | 66 (99%) | 1 (1%) | 67 |
| Paraguay | 0 (0%) | 39 (98%) | 1 (2%) | 40 |
| Total | 40 | 176 | 55 | 271 |
Samples co-positive by TSSA-WB and CS were considered. Data represent the lineage distribution analysis for countries, with comparisons between TSSA reactivity (I vs. II; II vs. I–II; I vs. I–II) being performed with the χ2 or Fisher exact tests. Overall difference was P < 0.00001 (χ2 test, degrees of freedom (df) = 8). Comparisons of TSSA reactivity between southern countries (Argentina and Paraguay) were not significant. Comparisons of TSSA reactivity among northern countries (Mexico, Venezuela, and Colombia) remained insignificant except for TSSA I vs. TSSA I–II reactivity between Venezuela and Colombia (P < 0.025; χ2 test, df = 1). Comparison for lineage distribution on dividing into northern (Mexico, Venezuela, and Colombia) and southern (Paraguay and Argentina) countries: overall difference P < 0.00001 (χ2, df = 2); TSSA I vs. TSSA II: P < 0.0001 (χ2, df = 1); TSSA II vs. TSSA I–II: P < 0.0001 (χ2, df = 1). Comparisons of TSSA I vs. TSSA I/II reactivity were not significant.